



Clinical trial results:

A Double-blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Mixed Dyslipidemia Summary

EudraCT number	2021-000688-57
Trial protocol	HU PL
Global end of trial date	14 August 2023

Results information

Result version number	v1 (current)
This version publication date	28 August 2024
First version publication date	28 August 2024

Trial information

Trial identification

Sponsor protocol code	AROAPOC3-2002
-----------------------	---------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04998201
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Arrowhead Pharmaceuticals, Inc.
Sponsor organisation address	177 East Colorado Boulevard, Suite 700, Pasadena, CA, United States, 91105
Public contact	Chief Operating Officer, Arrowhead Pharmaceuticals, Inc., +1 626-304-3400, info@arrowheadpharma.com
Scientific contact	Chief Operating Officer, Arrowhead Pharmaceuticals, Inc., +1 626-304-3400, info@arrowheadpharma.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 August 2023
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	14 August 2023
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study was to evaluate the safety and efficacy of ARO-APOC3 in adults with mixed dyslipidemia (MD) and to select a dose and dosing regimen for later stage clinical studies in this patient population.

Protection of trial subjects:

All eligible participants had the study explained by the PI or designee. They received a full explanation, in lay terms, of the aims of the study, the discomforts, risks and benefits in taking part as well as of insurance and other procedures for compensation in case of injury. It was explained that the study is for research purposes only and was not expected to provide any therapeutic benefit to the individual. It was pointed out that they could withdraw from the study at any time without prejudice.

Background therapy:

All subjects were required to maintain a stable regimen of optimal statin therapy during screening and throughout the treatment period.

Evidence for comparator: -

Actual start date of recruitment	07 September 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 38
Country: Number of subjects enrolled	Australia: 10
Country: Number of subjects enrolled	New Zealand: 12
Country: Number of subjects enrolled	United States: 169
Country: Number of subjects enrolled	Poland: 18
Country: Number of subjects enrolled	Hungary: 106
Worldwide total number of subjects	353
EEA total number of subjects	124

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	206
From 65 to 84 years	145
85 years and over	2

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Participants who successfully passed the requirements during the Screening period were enrolled into the study. All dose cohorts were enrolled in parallel with participants randomized 3:1 to receive ARO-APOC3 or placebo.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Blinding implementation details:

Treatment assignment (active versus placebo) was blinded in this clinical study. Dose group assignment was not blinded, due to required injection volume differences dictated by the respective dose group. Therefore, participants received an injection of either active or placebo volume matched to the assigned dose group. Syringes were blinded in the Pharmacy with translucent wrapping to mask the blinded staff and participants to treatment assignment in accordance with instructions provided.

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Volume-matched placebo at Day 1 and Week 12

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subcutaneous (SC) injection on Day 1 and Week 12 for a total of 2 injections

Arm title	ARO-APOC3 10 mg Q12W
------------------	----------------------

Arm description:

ARO-APOC3 10 mg at Day 1 and Week 12 (Q12W)

Arm type	Experimental
Investigational medicinal product name	ARO-APOC3 Injection
Investigational medicinal product code	ARO-APOC3
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

SC injection on Day 1 and Week 12 for a total of 2 injections

Arm title	ARO-APOC3 25mg Q12W
------------------	---------------------

Arm description:

ARO-APOC3 25 mg at Day 1 and Week 12 (Q12W)

Arm type	Experimental
----------	--------------

Investigational medicinal product name	ARO-APOC3 Injection
Investigational medicinal product code	ARO-APOC3
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
SC injection on Day 1 and Week 12 for a total of 2 injections	
Arm title	ARO-APOC3 50mg Q12W
Arm description:	
ARO-APOC3 50 mg (n=60) or volume-matched placebo (n=20) at Day 1 and Week 12 (Q12W)	
Arm type	Experimental
Investigational medicinal product name	ARO-APOC3 Injection
Investigational medicinal product code	ARO-APOC3
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
SC injection on Day 1 and Week 12 for a total of 2 injections	
Arm title	ARO-APOC3 50mg Q24W
Arm description:	
ARO-APOC3 50 mg at Day 1 and Week 24 (Q24W)	
Arm type	Experimental
Investigational medicinal product name	ARO-APOC3 Injection
Investigational medicinal product code	ARO-APOC3
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
SC injection on Day 1 and Week 24 for a total of 2 injections	

Number of subjects in period 1	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W
Started	87	67	67
Completed	78	60	64
Not completed	9	7	3
Consent withdrawn by subject	3	3	1
Physician decision	3	1	-
Death	-	-	1
Other, not specified	-	-	-
Adverse event	-	1	-
Lost to follow-up	2	2	1
Protocol deviation	1	-	-

Number of subjects in period 1	ARO-APOC3 50mg Q12W	ARO-APOC3 50mg Q24W
Started	66	66

Completed	61	61
Not completed	5	5
Consent withdrawn by subject	1	2
Physician decision	2	-
Death	-	1
Other, not specified	-	1
Adverse event	-	1
Lost to follow-up	1	-
Protocol deviation	1	-

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description: Volume-matched placebo at Day 1 and Week 12	
Reporting group title	ARO-APOC3 10 mg Q12W
Reporting group description: ARO-APOC3 10 mg at Day 1 and Week 12 (Q12W)	
Reporting group title	ARO-APOC3 25mg Q12W
Reporting group description: ARO-APOC3 25 mg at Day 1 and Week 12 (Q12W)	
Reporting group title	ARO-APOC3 50mg Q12W
Reporting group description: ARO-APOC3 50 mg (n=60) or volume-matched placebo (n=20) at Day 1 and Week 12 (Q12W)	
Reporting group title	ARO-APOC3 50mg Q24W
Reporting group description: ARO-APOC3 50 mg at Day 1 and Week 24 (Q24W)	

Reporting group values	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W
Number of subjects	87	67	67
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	58.9	60.2	61.3
standard deviation	± 9.70	± 11.71	± 11.28
Gender categorical			
Units: Subjects			
Female	41	31	37
Male	46	36	30
Ethnicity			
Units: Subjects			
Hispanic or Latino	16	18	12
Not Hispanic or Latino	71	49	55
Not Reported	0	0	0
Race			
Units: Subjects			
White	79	62	60
Black or African American	4	2	2
American Indian or Alaska Native	0	0	1
Asian	3	2	3
Native Hawaiian or Other Pacific Islander	0	0	1
Unknown	0	0	0
Other	1	1	0

Mean Triglycerides (TG)			
Units: mg/dL			
arithmetic mean	237.22	253.15	234.08
standard deviation	± 76.179	± 81.425	± 72.746

Reporting group values	ARO-APOC3 50mg Q12W	ARO-APOC3 50mg Q24W	Total
Number of subjects	66	66	353
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	62.6	61.3	
standard deviation	± 10.53	± 11.84	-
Gender categorical			
Units: Subjects			
Female	37	43	189
Male	29	23	164
Ethnicity			
Units: Subjects			
Hispanic or Latino	12	15	73
Not Hispanic or Latino	53	51	279
Not Reported	1	0	1
Race			
Units: Subjects			
White	63	62	326
Black or African American	0	0	8
American Indian or Alaska Native	0	0	1
Asian	1	1	10
Native Hawaiian or Other Pacific Islander	0	1	2
Unknown	0	1	1
Other	2	1	5
Mean Triglycerides (TG)			
Units: mg/dL			
arithmetic mean	250.25	248.01	
standard deviation	± 81.329	± 80.553	-

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description: Volume-matched placebo at Day 1 and Week 12	
Reporting group title	ARO-APOC3 10 mg Q12W
Reporting group description: ARO-APOC3 10 mg at Day 1 and Week 12 (Q12W)	
Reporting group title	ARO-APOC3 25mg Q12W
Reporting group description: ARO-APOC3 25 mg at Day 1 and Week 12 (Q12W)	
Reporting group title	ARO-APOC3 50mg Q12W
Reporting group description: ARO-APOC3 50 mg (n=60) or volume-matched placebo (n=20) at Day 1 and Week 12 (Q12W)	
Reporting group title	ARO-APOC3 50mg Q24W
Reporting group description: ARO-APOC3 50 mg at Day 1 and Week 24 (Q24W)	

Primary: Percent Change From Baseline at Week 24 in Fasting TG

End point title	Percent Change From Baseline at Week 24 in Fasting TG
End point description: Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). Observed cases.	
End point type	Primary
End point timeframe: Baseline, Week 24	

End point values	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W	ARO-APOC3 50mg Q12W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	81	61	63	62
Units: percentage change				
least squares mean (standard error)	-1.7 (± 3.07)	-51.5 (± 3.54)	-57.7 (± 3.49)	-64.1 (± 3.51)

End point values	ARO-APOC3 50mg Q24W			
Subject group type	Reporting group			
Number of subjects analysed	61			
Units: percentage change				
least squares mean (standard error)	-45.9 (± 3.52)			

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v ARO-APOC3 10 mg Q12W
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[1]
Method	MMRM
Parameter estimate	Difference
Point estimate	-49.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-59
upper limit	-40.6

Notes:

[1] - Mixed Model Repeated Measures (MMRM) model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms.

Statistical analysis title	Statistical Analysis 2
Comparison groups	Placebo v ARO-APOC3 25mg Q12W
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[2]
Method	MMRM
Parameter estimate	Difference
Point estimate	-56
Confidence interval	
level	95 %
sides	2-sided
lower limit	-65.1
upper limit	-46.8

Notes:

[2] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms.

Statistical analysis title	Statistical Analysis 3
Comparison groups	Placebo v ARO-APOC3 50mg Q12W

Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[3]
Method	MMRM
Parameter estimate	Difference
Point estimate	-62.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-71.5
upper limit	-53.2

Notes:

[3] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms.

Statistical analysis title	Statistical Analysis 4
Comparison groups	Placebo v ARO-APOC3 50mg Q24W
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[4]
Method	MMRM
Parameter estimate	Difference
Point estimate	-44.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-53.4
upper limit	-35

Notes:

[4] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms.

Secondary: Percent Change From Baseline Over Time Through Week 48 in Fasting TG

End point title	Percent Change From Baseline Over Time Through Week 48 in Fasting TG
-----------------	--

End point description:

Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). n=Observed cases at given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)

End point values	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W	ARO-APOC3 50mg Q12W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	87	67	67	66
Units: percentage change				
least squares mean (standard error)				
Week 4; n=85, 62, 67, 63, 63	-0.5 (± 2.77)	-51.4 (± 3.21)	-61.5 (± 3.14)	-66.4 (± 3.20)
Week 8; n=83, 64, 66, 64, 64	-0.4 (± 2.45)	-48.6 (± 2.78)	-58.1 (± 2.77)	-65.0 (± 2.78)
Week 12; n=80, 63, 61, 64, 61	-0.1 (± 3.07)	-43.8 (± 3.46)	-53.6 (± 3.50)	-57.9 (± 3.45)
Week 16; n=77, 63, 63, 63, 65	-1.8 (± 2.87)	-58.0 (± 3.21)	-62.0 (± 3.21)	-68.3 (± 3.21)
Week 20; n=82, 59, 61, 61, 63	1.2 (± 2.85)	-54.6 (± 3.32)	-62.0 (± 3.28)	-64.7 (± 3.28)
Week 24; n=81, 61, 63, 62, 61	-1.7 (± 3.07)	-51.5 (± 3.54)	-57.7 (± 3.49)	-64.1 (± 3.51)
Week 28; n=82, 61, 64, 62, 61	3.5 (± 2.95)	-46.2 (± 3.41)	-55.7 (± 3.35)	-61.7 (± 3.38)
Week 36; n=80, 61, 63, 60, 61	6.1 (± 4.66)	-44.7 (± 5.35)	-51.5 (± 5.25)	-54.9 (± 5.34)
Week 48; n=78, 60, 64, 61, 61	1.7 (± 4.35)	-33.2 (± 4.96)	-42.8 (± 4.86)	-50.2 (± 4.94)

End point values	ARO-APOC3 50mg Q24W			
Subject group type	Reporting group			
Number of subjects analysed	66			
Units: percentage change				
least squares mean (standard error)				
Week 4; n=85, 62, 67, 63, 63	-62.5 (± 3.19)			
Week 8; n=83, 64, 66, 64, 64	-59.7 (± 2.78)			
Week 12; n=80, 63, 61, 64, 61	-51.7 (± 3.49)			
Week 16; n=77, 63, 63, 63, 65	-50.6 (± 3.17)			
Week 20; n=82, 59, 61, 61, 63	-49.1 (± 3.23)			
Week 24; n=81, 61, 63, 62, 61	-45.9 (± 3.52)			
Week 28; n=82, 61, 64, 62, 61	-63.4 (± 3.39)			
Week 36; n=80, 61, 63, 60, 61	-60.1 (± 5.32)			
Week 48; n=78, 60, 64, 61, 61	-55.0 (± 4.93)			

Attachments (see zip file)	Percent Change from Baseline Over Time Through Week 48 in
-----------------------------------	---

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline at Week 24 in Apolipoprotein (Apo)C-III

End point title	Percent Change From Baseline at Week 24 in Apolipoprotein (Apo)C-III
End point description:	
Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). Observed cases.	
End point type	Secondary
End point timeframe:	
Baseline, Week 24	

End point values	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W	ARO-APOC3 50mg Q12W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	79	59	63	62
Units: percentage change				
least squares mean (standard error)	23.9 (± 21.90)	-58.9 (± 24.86)	-44.3 (± 24.54)	-65.7 (± 24.71)

End point values	ARO-APOC3 50mg Q24W			
Subject group type	Reporting group			
Number of subjects analysed	61			
Units: percentage change				
least squares mean (standard error)	-57.9 (± 24.70)			

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v ARO-APOC3 10 mg Q12W
Number of subjects included in analysis	138
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0128 ^[5]
Method	MMRM
Parameter estimate	Difference
Point estimate	-82.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-147.9
upper limit	-17.7

Notes:

[5] - Mixed Model Repeated Measures (MMRM) model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms.

Statistical analysis title	Statistical Analysis 2
Comparison groups	Placebo v ARO-APOC3 25mg Q12W

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0387 ^[6]
Method	MMRM
Parameter estimate	Difference
Point estimate	-68.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-132.9
upper limit	-3.5

Notes:

[6] - Mixed Model Repeated Measures (MMRM) model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms.

Statistical analysis title	Statistical Analysis 3
Comparison groups	Placebo v ARO-APOC3 50mg Q12W
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0069 ^[7]
Method	MMRM
Parameter estimate	Difference
Point estimate	-89.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-154.5
upper limit	-24.7

Notes:

[7] - Mixed Model Repeated Measures (MMRM) model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms.

Statistical analysis title	Statistical Analysis 4
Comparison groups	Placebo v ARO-APOC3 50mg Q24W
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0136 ^[8]
Method	MMRM
Parameter estimate	Difference
Point estimate	-81.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-146.7
upper limit	-16.9

Notes:

[8] - Mixed Model Repeated Measures (MMRM) model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms.

Secondary: Percent Change From Baseline Over Time Through Week 48 in Apolipoprotein (Apo)C-III

End point title	Percent Change From Baseline Over Time Through Week 48 in Apolipoprotein (Apo)C-III
-----------------	---

End point description:

Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP).
n=Observed cases at given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)

End point values	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W	ARO-APOC3 50mg Q12W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	87	67	67	66
Units: percentage change				
least squares mean (standard error)				
Week 4; n=84, 61, 67, 63, 63	19.3 (± 21.81)	-60.7 (± 24.78)	-69.7 (± 24.45)	-78.4 (± 24.66)
Week 8; n=81, 63, 65, 64, 64	19.0 (± 21.84)	-57.3 (± 24.72)	-61.9 (± 24.48)	-71.8 (± 24.64)
Week 12; n=79, 62, 61, 64, 61	20.3 (± 21.90)	-48.7 (± 24.77)	-18.9 (± 24.57)	-59.2 (± 24.66)
Week 16; n=77, 62, 63, 64, 65	10.9 (± 21.92)	-69.9 (± 24.79)	-63.8 (± 24.54)	-78.9 (± 24.67)
Week 20; n=80, 58, 60, 61, 63	21.8 (± 21.88)	-64.0 (± 24.87)	-63.3 (± 24.58)	-69.3 (± 24.72)
Week 24; n=79, 59, 63, 62, 61	23.9 (± 21.90)	-58.9 (± 24.86)	-44.3 (± 24.54)	-65.7 (± 24.71)
Week 28; n=81, 60, 64, 62, 62	35.6 (± 21.90)	-51.7 (± 24.87)	-32.8 (± 24.55)	-53.3 (± 24.71)
Week 36; n=79, 60, 63, 60, 61	30.6 (± 21.96)	-46.3 (± 24.91)	-24.9 (± 24.58)	-34.5 (± 24.74)
Week 48; n=77, 59, 64, 61, 61	27.3 (± 21.97)	-31.2 (± 24.97)	-13.9 (± 24.58)	-17.4 (± 24.78)

End point values	ARO-APOC3 50mg Q24W			
Subject group type	Reporting group			
Number of subjects analysed	66			
Units: percentage change				
least squares mean (standard error)				
Week 4; n=84, 61, 67, 63, 63	-82.7 (± 24.64)			
Week 8; n=81, 63, 65, 64, 64	-78.1 (± 24.62)			
Week 12; n=79, 62, 61, 64, 61	-71.5 (± 24.68)			

Week 16; n=77, 62, 63, 64, 65	-67.7 (± 24.62)			
Week 20; n=80, 58, 60, 61, 63	-62.6 (± 24.65)			
Week 24; n=79, 59, 63, 62, 61	-57.9 (± 24.70)			
Week 28; n=81, 60, 64, 62, 62	-82.5 (± 24.70)			
Week 36; n=79, 60, 63, 60, 61	-75.8 (± 24.70)			
Week 48; n=77, 59, 64, 61, 61	-64.8 (± 24.72)			

Attachments (see zip file)	Percent Change from Baseline at Week 24 and Over Time
-----------------------------------	---

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline at Week 24 in Fasting Non-High-Density Lipoprotein Cholesterol (non-HDL-C)

End point title	Percent Change From Baseline at Week 24 in Fasting Non-High-Density Lipoprotein Cholesterol (non-HDL-C)
End point description:	
Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). Observed cases.	
End point type	Secondary
End point timeframe:	
Baseline, Week 24	

End point values	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W	ARO-APOC3 50mg Q12W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	81	61	63	62
Units: percentage change				
least squares mean (standard error)	-2.7 (± 2.56)	-19.3 (± 2.93)	-20.1 (± 2.90)	-26.9 (± 2.92)

End point values	ARO-APOC3 50mg Q24W			
Subject group type	Reporting group			
Number of subjects analysed	61			
Units: percentage change				
least squares mean (standard error)	-10.3 (± 2.92)			

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v ARO-APOC3 10 mg Q12W
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[9]
Method	MMRM
Parameter estimate	Difference
Point estimate	-16.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.3
upper limit	-9

Notes:

[9] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

Statistical analysis title	Statistical Analysis 2
Comparison groups	Placebo v ARO-APOC3 25mg Q12W
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[10]
Method	MMRM
Parameter estimate	Difference
Point estimate	-17.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.1
upper limit	-9.8

Notes:

[10] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

Statistical analysis title	Statistical Analysis 3
Comparison groups	Placebo v ARO-APOC3 50mg Q12W
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[11]
Method	MMRM
Parameter estimate	Difference
Point estimate	-24.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-31.9
upper limit	-16.6

Notes:

[11] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

Statistical analysis title	Statistical Analysis 4
Comparison groups	Placebo v ARO-APOC3 50mg Q24W
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0492 ^[12]
Method	MMRM
Parameter estimate	Difference
Point estimate	-7.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.3
upper limit	0

Notes:

[12] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

Secondary: Percent Change From Baseline Over Time Through Week 48 in Fasting Non-High-Density Lipoprotein Cholesterol (non-HDL-C)

End point title	Percent Change From Baseline Over Time Through Week 48 in Fasting Non-High-Density Lipoprotein Cholesterol (non-HDL-C)
-----------------	--

End point description:

Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). n=Observed cases at given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)

End point values	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W	ARO-APOC3 50mg Q12W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	87	67	67	66
Units: percentage change				
least squares mean (standard error)				
Week 4; n=85, 62, 67, 63, 63	-1.2 (± 2.19)	-17.3 (± 2.53)	-23.3 (± 2.48)	-26.3 (± 2.52)
Week 8; n=83, 64, 66, 64, 64	-1.0 (± 2.37)	-18.2 (± 2.69)	-22.4 (± 2.67)	-27.8 (± 2.70)
Week 12; n=80, 63, 61, 64, 61	-0.4 (± 2.65)	-15.5 (± 3.00)	-19.4 (± 3.01)	-21.9 (± 3.00)
Week 16; n=77, 63, 63, 63, 65	-1.4 (± 2.49)	-21.2 (± 2.80)	-23.8 (± 2.80)	-28.5 (± 2.81)
Week 20; n=82, 59, 61, 61, 63	-1.9 (± 2.82)	-20.9 (± 3.24)	-21.5 (± 3.21)	-27.3 (± 3.22)
Week 24; n=81, 61, 63, 62, 61	-2.7 (± 2.56)	-19.3 (± 2.93)	-20.1 (± 2.90)	-26.9 (± 2.92)
Week 28; n=82, 61, 64, 62, 61	0.4 (± 2.91)	-17.1 (± 3.33)	-17.7 (± 3.29)	-25.6 (± 3.32)
Week 36; n=80, 61, 63, 60, 61	0.0 (± 2.71)	-17.1 (± 3.09)	-17.1 (± 3.05)	-23.4 (± 3.10)
Week 48; n=78, 60, 64, 61, 61	1.7 (± 2.96)	-12.1 (± 3.37)	-12.1 (± 3.29)	-21.8 (± 3.35)

End point values	ARO-APOC3 50mg Q24W			
Subject group type	Reporting group			
Number of subjects analysed	66			
Units: percentage change				
least squares mean (standard error)				
Week 4; n=85, 62, 67, 63, 63	-19.6 (± 2.53)			
Week 8; n=83, 64, 66, 64, 64	-16.2 (± 2.70)			
Week 12; n=80, 63, 61, 64, 61	-16.0 (± 3.02)			
Week 16; n=77, 63, 63, 63, 65	-15.5 (± 2.79)			
Week 20; n=82, 59, 61, 61, 63	-11.7 (± 3.20)			
Week 24; n=81, 61, 63, 62, 61	-10.3 (± 2.92)			
Week 28; n=82, 61, 64, 62, 61	-20.5 (± 3.33)			
Week 36; n=80, 61, 63, 60, 61	-17.3 (± 3.09)			
Week 48; n=78, 60, 64, 61, 61	-20.0 (± 3.35)			

Attachments (see zip file)	Percent Change from Baseline at Week 24 and Over Time
-----------------------------------	---

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline at Week 24 in Fasting High-Density Lipoprotein Cholesterol (HDL-C)

End point title	Percent Change From Baseline at Week 24 in Fasting High-Density Lipoprotein Cholesterol (HDL-C)
End point description:	
Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). Observed cases.	
End point type	Secondary
End point timeframe:	
Baseline, Week 24	

End point values	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W	ARO-APOC3 50mg Q12W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	81	61	63	62
Units: percentage change				
least squares mean (standard error)	4.7 (± 3.34)	37.9 (± 3.81)	46.8 (± 3.82)	50.5 (± 3.80)

End point values	ARO-APOC3			
-------------------------	-----------	--	--	--

	50mg Q24W			
Subject group type	Reporting group			
Number of subjects analysed	61			
Units: percentage change				
least squares mean (standard error)	32.8 (\pm 3.82)			

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	ARO-APOC3 10 mg Q12W v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[13]
Method	MMRM
Parameter estimate	Difference
Point estimate	33.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	23.2
upper limit	43.1

Notes:

[13] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

Statistical analysis title	Statistical Analysis 2
Comparison groups	Placebo v ARO-APOC3 25mg Q12W
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[14]
Method	MMRM
Parameter estimate	Difference
Point estimate	42
Confidence interval	
level	95 %
sides	2-sided
lower limit	32.1
upper limit	52

Notes:

[14] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

Statistical analysis title	Statistical Analysis 3
Comparison groups	Placebo v ARO-APOC3 50mg Q12W

Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[15]
Method	MMRM
Parameter estimate	Difference
Point estimate	45.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	35.8
upper limit	55.7

Notes:

[15] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

Statistical analysis title	Statistical Analysis 4
Comparison groups	Placebo v ARO-APOC3 50mg Q24W
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[16]
Method	MMRM
Parameter estimate	Difference
Point estimate	28
Confidence interval	
level	95 %
sides	2-sided
lower limit	18
upper limit	38

Notes:

[16] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

Secondary: Percent Change From Baseline Over Time Through Week 48 in Fasting High-Density Lipoprotein Cholesterol (HDL-C)

End point title	Percent Change From Baseline Over Time Through Week 48 in Fasting High-Density Lipoprotein Cholesterol (HDL-C)
End point description:	
Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). n=Participants with an assessment at given time point.	
End point type	Secondary
End point timeframe:	
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)	

End point values	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W	ARO-APOC3 50mg Q12W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	87	67	67	66
Units: percentage change				
least squares mean (standard error)				
Week 4; n=85, 62, 67, 63, 63	3.6 (± 3.38)	39.3 (± 3.88)	48.3 (± 3.86)	55.4 (± 3.88)
Week 8; n=83, 64, 66, 64, 64	2.0 (± 3.18)	32.1 (± 3.61)	46.4 (± 3.63)	54.3 (± 3.62)
Week 12; n=80, 63, 61, 64, 61	2.5 (± 3.19)	31.4 (± 3.60)	40.1 (± 3.66)	49.0 (± 3.61)
Week 16; n=77, 63, 63, 63, 65	3.2 (± 3.46)	45.8 (± 3.90)	56.4 (± 3.93)	64.2 (± 3.91)
Week 20; n=82, 59, 61, 61, 63	2.8 (± 3.27)	45.0 (± 3.75)	50.6 (± 3.76)	58.2 (± 3.74)
Week 24; n=81, 61, 63, 62, 61	4.7 (± 3.34)	37.9 (± 3.81)	46.8 (± 3.82)	50.5 (± 3.80)
Week 28; n=82, 61, 64, 62, 61	2.1 (± 3.47)	35.8 (± 3.98)	45.3 (± 3.96)	49.5 (± 3.96)
Week 36; n=80, 61, 63, 60, 61	1.6 (± 3.25)	30.8 (± 3.72)	37.0 (± 3.71)	43.1 (± 3.72)
Week 48; n=78, 60, 64, 61, 61	4.5 (± 3.53)	25.4 (± 4.02)	30.5 (± 3.98)	34.3 (± 4.00)

End point values	ARO-APOC3 50mg Q24W			
Subject group type	Reporting group			
Number of subjects analysed	66			
Units: percentage change				
least squares mean (standard error)				
Week 4; n=85, 62, 67, 63, 63	55.5 (± 3.90)			
Week 8; n=83, 64, 66, 64, 64	52.8 (± 3.64)			
Week 12; n=80, 63, 61, 64, 61	45.1 (± 3.65)			
Week 16; n=77, 63, 63, 63, 65	41.6 (± 3.91)			
Week 20; n=82, 59, 61, 61, 63	40.3 (± 3.73)			
Week 24; n=81, 61, 63, 62, 61	32.8 (± 3.82)			
Week 28; n=82, 61, 64, 62, 61	54.0 (± 3.99)			
Week 36; n=80, 61, 63, 60, 61	49.7 (± 3.73)			
Week 48; n=78, 60, 64, 61, 61	44.5 (± 4.01)			

Attachments (see zip file)	Percent Change from Baseline at Week 24 and Over Time
-----------------------------------	---

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline at Week 24 in Fasting Total Apolipoprotein B (ApoB)

End point title	Percent Change From Baseline at Week 24 in Fasting Total Apolipoprotein B (ApoB)
End point description:	
Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). Participants with an assessment at given time point.	
End point type	Secondary
End point timeframe:	
Baseline, Week 24	

End point values	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W	ARO-APOC3 50mg Q12W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	79	59	63	62
Units: percentage change				
least squares mean (standard error)	0.8 (± 2.57)	-9.5 (± 2.94)	-12.2 (± 2.89)	-18.3 (± 2.91)

End point values	ARO-APOC3 50mg Q24W			
Subject group type	Reporting group			
Number of subjects analysed	61			
Units: percentage change				
least squares mean (standard error)	-5.7 (± 2.91)			

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v ARO-APOC3 10 mg Q12W
Number of subjects included in analysis	138
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0089 ^[17]
Method	MMRM
Parameter estimate	Difference
Point estimate	-10.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.9
upper limit	-2.6

Notes:

[17] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

Statistical analysis title	Statistical Analysis 2
Comparison groups	Placebo v ARO-APOC3 25mg Q12W
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0009 ^[18]
Method	MMRM
Parameter estimate	Difference
Point estimate	-13

Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.6
upper limit	-5.4

Notes:

[18] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

Statistical analysis title	Statistical Analysis 3
Comparison groups	Placebo v ARO-APOC3 50mg Q12W
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[19]
Method	MMRM
Parameter estimate	Difference
Point estimate	-19.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.7
upper limit	-11.5

Notes:

[19] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

Statistical analysis title	Statistical Analysis 4
Comparison groups	Placebo v ARO-APOC3 50mg Q24W
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0965 ^[20]
Method	MMRM
Parameter estimate	Difference
Point estimate	-6.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.1
upper limit	1.2

Notes:

[20] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

Secondary: Percent Change From Baseline Over Time Through Week 48 in Fasting Total Apolipoprotein B (ApoB)

End point title	Percent Change From Baseline Over Time Through Week 48 in Fasting Total Apolipoprotein B (ApoB)
-----------------	---

End point description:

Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP).
n=Participants with an assessment at given time point.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)	

End point values	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W	ARO-APOC3 50mg Q12W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	87	67	67	66
Units: percentage change				
least squares mean (standard error)				
Week 4; n=84, 61, 67, 63, 63	-1.3 (± 1.99)	-10.3 (± 2.30)	-15.5 (± 2.24)	-18.5 (± 2.28)
Week 8; n=81, 63, 65, 64, 64	-0.5 (± 2.26)	-11.0 (± 2.56)	-15.5 (± 2.54)	-20.3 (± 2.55)
Week 12; n=79, 62, 61, 64, 61	0.9 (± 2.53)	-8.5 (± 2.87)	-14.3 (± 2.86)	-14.8 (± 2.85)
Week 16; n=77, 62, 63, 64, 65	0.2 (± 2.30)	-12.8 (± 2.60)	-17.2 (± 2.57)	-20.6 (± 2.58)
Week 20; n=80, 58, 60, 61, 63	0.5 (± 2.61)	-13.0 (± 3.00)	-14.3 (± 2.96)	-19.3 (± 2.97)
Week 24; n=79, 59, 63, 62, 61	0.8 (± 2.57)	-9.5 (± 2.94)	-12.2 (± 2.89)	-18.3 (± 2.91)
Week 28; n=81, 60, 64, 62, 62	5.1 (± 2.98)	-9.0 (± 3.41)	-10.0 (± 3.35)	-16.3 (± 3.38)
Week 36; n=79, 60, 63, 60, 61	3.7 (± 2.68)	-7.8 (± 3.07)	-9.3 (± 3.00)	-15.4 (± 3.05)
Week 48; n=77, 59, 64, 61, 61	3.3 (± 2.75)	-4.7 (± 3.14)	-6.4 (± 3.06)	-12.2 (± 3.11)

End point values	ARO-APOC3 50mg Q24W			
Subject group type	Reporting group			
Number of subjects analysed	66			
Units: percentage change				
least squares mean (standard error)				
Week 4; n=84, 61, 67, 63, 63	-13.5 (± 2.29)			
Week 8; n=81, 63, 65, 64, 64	-10.9 (± 2.56)			
Week 12; n=79, 62, 61, 64, 61	-10.8 (± 2.87)			
Week 16; n=77, 62, 63, 64, 65	-9.4 (± 2.58)			
Week 20; n=80, 58, 60, 61, 63	-7.3 (± 2.95)			
Week 24; n=79, 59, 63, 62, 61	-5.7 (± 2.91)			
Week 28; n=81, 60, 64, 62, 62	-12.1 (± 3.38)			
Week 36; n=79, 60, 63, 60, 61	-9.9 (± 3.04)			
Week 48; n=77, 59, 64, 61, 61	-11.9 (± 3.11)			

Attachments (see zip file)	Percent Change from Baseline at Week 24 and Over Time
----------------------------	---

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline at Week 24 in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C)

End point title	Percent Change From Baseline at Week 24 in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C)
End point description:	
Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). Participants with an assessment at given time point.	
End point type	Secondary
End point timeframe:	
Baseline, Week 24	

End point values	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W	ARO-APOC3 50mg Q12W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	81	61	63	62
Units: percentage change				
least squares mean (standard error)	-0.1 (± 3.62)	1.4 (± 4.14)	3.9 (± 4.10)	-4.3 (± 4.13)

End point values	ARO-APOC3 50mg Q24W			
Subject group type	Reporting group			
Number of subjects analysed	61			
Units: percentage change				
least squares mean (standard error)	7.3 (± 4.14)			

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v ARO-APOC3 10 mg Q12W
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7856 ^[21]
Method	MMRM
Parameter estimate	Difference
Point estimate	1.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.3
upper limit	12.3

Notes:

[21] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

Statistical analysis title	Statistical Analysis 2
Comparison groups	Placebo v ARO-APOC3 25mg Q12W

Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4602 ^[22]
Method	MMRM
Parameter estimate	Difference
Point estimate	4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.7
upper limit	14.8

Notes:

[22] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

Statistical analysis title	Statistical Analysis 3
Comparison groups	Placebo v ARO-APOC3 50mg Q12W
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4429 ^[23]
Method	MMRM
Parameter estimate	Difference
Point estimate	-4.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15
upper limit	6.6

Notes:

[23] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

Statistical analysis title	Statistical Analysis 4
Comparison groups	Placebo v ARO-APOC3 50mg Q24W
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1763 ^[24]
Method	MMRM
Parameter estimate	Difference
Point estimate	7.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.4
upper limit	18.3

Notes:

[24] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

Secondary: Percent Change From Baseline Over Time Through Week 48 in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C)

End point title	Percent Change From Baseline Over Time Through Week 48 in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C)
-----------------	---

End point description:

Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP).
n=Participants with an assessment at given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)

End point values	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W	ARO-APOC3 50mg Q12W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	87	67	67	66
Units: percentage change				
least squares mean (standard error)				
Week 4; n=85, 62, 67, 63, 63	0.6 (± 3.18)	5.0 (± 3.67)	1.1 (± 3.59)	0.4 (± 3.66)
Week 8; n=83, 64, 66, 64, 64	1.7 (± 3.24)	0.7 (± 3.68)	0.6 (± 3.65)	-3.6 (± 3.69)
Week 12; n=80, 63, 61, 64, 61	1.8 (± 3.68)	2.5 (± 4.16)	2.5 (± 4.18)	1.6 (± 4.16)
Week 16; n=77, 63, 63, 63, 65	1.5 (± 3.65)	2.2 (± 4.11)	0.4 (± 4.10)	-2.7 (± 4.11)
Week 20; n=82, 59, 61, 61, 63	-0.3 (± 3.78)	1.3 (± 4.35)	4.0 (± 4.31)	-3.9 (± 4.33)
Week 24; n=81, 61, 63, 62, 61	-0.1 (± 3.62)	1.4 (± 4.14)	3.9 (± 4.10)	-4.3 (± 4.13)
Week 28; n=82, 61, 64, 62, 61	1.6 (± 3.86)	0.2 (± 4.42)	6.1 (± 4.37)	-3.6 (± 4.41)
Week 36; n=80, 61, 63, 60, 61	1.6 (± 3.80)	0.0 (± 4.33)	5.3 (± 4.28)	-3.5 (± 4.35)
Week 48; n=78, 60, 64, 61, 61	1.7 (± 3.88)	2.0 (± 4.43)	6.9 (± 4.32)	-4.0 (± 4.40)

End point values	ARO-APOC3 50mg Q24W			
Subject group type	Reporting group			
Number of subjects analysed	66			
Units: percentage change				
least squares mean (standard error)				
Week 4; n=85, 62, 67, 63, 63	3.2 (± 3.67)			
Week 8; n=83, 64, 66, 64, 64	7.4 (± 3.70)			
Week 12; n=80, 63, 61, 64, 61	3.2 (± 4.20)			
Week 16; n=77, 63, 63, 63, 65	3.2 (± 4.09)			
Week 20; n=82, 59, 61, 61, 63	7.2 (± 4.30)			
Week 24; n=81, 61, 63, 62, 61	7.3 (± 4.14)			
Week 28; n=82, 61, 64, 62, 61	2.0 (± 4.42)			
Week 36; n=80, 61, 63, 60, 61	5.7 (± 4.34)			
Week 48; n=78, 60, 64, 61, 61	-0.1 (± 4.40)			

Attachments (see zip file)	Percent Change from Baseline at Week 24 and Over Time
-----------------------------------	---

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

End point title	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
-----------------	---

End point description:

An adverse event (AE) is any untoward medical occurrence, which does not necessarily have to have a causal relationship with this treatment. A serious AE (SAE) is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction.

TEAEs are AEs that occur following investigational product (IP) administration or a pre-existing condition exacerbated following IP administration.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 48

End point values	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W	ARO-APOC3 50mg Q12W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	87	67	67	66
Units: participants				
All Treatment-Emergent Adverse Events (TEAEs)	55	46	45	47
Treatment-related TEAEs	8	7	9	12
Serious TEAEs	5	2	5	7
TEAEs leading to study drug discontinuation	2	0	0	1
Deaths	0	0	1	2

End point values	ARO-APOC3 50mg Q24W			
Subject group type	Reporting group			
Number of subjects analysed	66			
Units: participants				
All Treatment-Emergent Adverse Events (TEAEs)	49			
Treatment-related TEAEs	8			

Serious TEAEs	5			
TEAEs leading to study drug discontinuation	0			
Deaths	1			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to Week 48

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.0
--------------------	------

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Volume-matched placebo at Day 1 and Week 12

Reporting group title	ARO-APOC3 10 mg Q12W
-----------------------	----------------------

Reporting group description:

ARO-APOC3 10 mg at Day 1 and Week 12 (Q12W)

Reporting group title	ARO-APOC3 25mg Q12W
-----------------------	---------------------

Reporting group description:

ARO-APOC3 25 mg at Day 1 and Week 12 (Q12W)

Reporting group title	ARO-APOC3 50mg Q12W
-----------------------	---------------------

Reporting group description:

ARO-APOC3 50 mg (n=60) or volume-matched placebo (n=20) at Day 1 and Week 12 (Q12W)

Reporting group title	ARO-APOC3 50mg Q24W
-----------------------	---------------------

Reporting group description:

ARO-APOC3 50 mg at Day 1 and Week 24 (Q24W)

Serious adverse events	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 87 (5.75%)	2 / 67 (2.99%)	5 / 67 (7.46%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Parathyroid tumour benign			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cancer			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			

Aortic aneurysm rupture			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Artery dissection			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Completed suicide			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			

Ankle fracture			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meniscus injury			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Lacunar infarction			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Coeliac artery aneurysm			

subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Subcutaneous abscess			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal abscess			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

COVID-19			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Postoperative wound infection			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypomagnesaemia			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	ARO-APOC3 50mg Q12W	ARO-APOC3 50mg Q24W	
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 66 (10.61%)	5 / 66 (7.58%)	
number of deaths (all causes)	2	1	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Parathyroid tumour benign			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Aortic aneurysm rupture			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Artery dissection			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Multiple organ dysfunction syndrome			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Asthma			

subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Completed suicide			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus injury			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			

subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial ischaemia			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Lacunar infarction			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Coeliac artery aneurysm			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			

subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Subcutaneous abscess			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal abscess			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			

subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypomagnesaemia			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Placebo	ARO-APOC3 10 mg Q12W	ARO-APOC3 25mg Q12W
Total subjects affected by non-serious adverse events			
subjects affected / exposed	55 / 87 (63.22%)	47 / 67 (70.15%)	44 / 67 (65.67%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Seborrhoeic keratosis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Adrenal adenoma			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Basal cell carcinoma			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Benign neoplasm of skin			

subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Blepharal papilloma			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Fibroma			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Lipoma			
subjects affected / exposed	1 / 87 (1.15%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	1	1	0
Malignant melanoma in situ			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Melanocytic naevus			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	3 / 87 (3.45%)	2 / 67 (2.99%)	2 / 67 (2.99%)
occurrences (all)	3	2	2
Blood pressure inadequately controlled			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Aortic aneurysm			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Aortic stenosis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Haematoma			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Hot flush			

subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Orthostatic hypotension			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 87 (1.15%)	1 / 67 (1.49%)	2 / 67 (2.99%)
occurrences (all)	1	1	2
Injection site erythema			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Influenza like illness			
subjects affected / exposed	3 / 87 (3.45%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	4	0	1
Oedema			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Peripheral swelling			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Swelling face			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Dystrophic calcification			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Injection site pain			

subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Injection site reaction			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Secretion discharge			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Sensation of foreign body			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Immune system disorders			
Food allergy			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Seasonal allergy			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Social circumstances			
Postmenopause			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Erectile dysfunction			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Fibrocystic breast disease			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Prostatomegaly			

subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Emphysema			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 87 (1.15%)	1 / 67 (1.49%)	2 / 67 (2.99%)
occurrences (all)	1	1	2
Dyspnoea			
subjects affected / exposed	2 / 87 (2.30%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	2	0	0
Nasal congestion			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Asthma			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Hydrothorax			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract inflammation			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Acquired diaphragmatic eventration			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Bronchial hyperreactivity			
subjects affected / exposed	2 / 87 (2.30%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	2	0	0
Bronchiectasis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Chronic obstructive pulmonary disease			

subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Dry throat			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Obstructive sleep apnoea syndrome			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Oropharyngeal pain			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	2 / 67 (2.99%)
occurrences (all)	2	0	2
Rhinorrhoea			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Upper-airway cough syndrome			
subjects affected / exposed	1 / 87 (1.15%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	1	1	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	2 / 67 (2.99%)
occurrences (all)	0	0	2
Anxiety			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	1 / 67 (1.49%)
occurrences (all)	0	1	1
Bipolar disorder			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Depression			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Investigations			
Blood urine present			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Glycosylated haemoglobin increased			

subjects affected / exposed	2 / 87 (2.30%)	2 / 67 (2.99%)	1 / 67 (1.49%)
occurrences (all)	2	2	1
Amylase increased			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	1	0	1
Blood creatine phosphokinase increased			
subjects affected / exposed	2 / 87 (2.30%)	1 / 67 (1.49%)	3 / 67 (4.48%)
occurrences (all)	2	1	3
Blood creatinine increased			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Blood pressure increased			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	2 / 67 (2.99%)
occurrences (all)	0	0	2
Blood urea increased			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Glomerular filtration rate decreased			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Haemoglobin decreased			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	2 / 67 (2.99%)
occurrences (all)	0	0	2
Lipase increased			
subjects affected / exposed	2 / 87 (2.30%)	1 / 67 (1.49%)	3 / 67 (4.48%)
occurrences (all)	4	1	3
Pancreatic enzymes increased			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Troponin increased			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0

Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	1 / 67 (1.49%) 1	0 / 67 (0.00%) 0
Anion gap increased subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	2 / 67 (2.99%) 2	1 / 67 (1.49%) 1
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	2 / 67 (2.99%) 2	0 / 67 (0.00%) 0
Bilirubin conjugated increased subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 67 (0.00%) 0	0 / 67 (0.00%) 0
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 67 (0.00%) 0	0 / 67 (0.00%) 0
Blood glucose increased subjects affected / exposed occurrences (all)	1 / 87 (1.15%) 1	1 / 67 (1.49%) 2	0 / 67 (0.00%) 0
Blood insulin increased subjects affected / exposed occurrences (all)	3 / 87 (3.45%) 3	1 / 67 (1.49%) 1	0 / 67 (0.00%) 0
Blood iron decreased subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	1 / 67 (1.49%) 1	0 / 67 (0.00%) 0
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	1 / 67 (1.49%) 1	0 / 67 (0.00%) 0
Blood uric acid increased subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	1 / 67 (1.49%) 1	2 / 67 (2.99%) 2
C-reactive protein increased subjects affected / exposed occurrences (all)	2 / 87 (2.30%) 3	1 / 67 (1.49%) 1	0 / 67 (0.00%) 0
Cardiac murmur			

subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Cells in urine			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Electrocardiogram T wave inversion			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram abnormal			
subjects affected / exposed	2 / 87 (2.30%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	2	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	1 / 67 (1.49%)
occurrences (all)	0	1	1
Haematocrit increased			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Human metapneumovirus test positive			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Insulin C-peptide increased			
subjects affected / exposed	2 / 87 (2.30%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	2	1	0
International normalised ratio increased			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Laboratory test abnormal			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	1 / 67 (1.49%)
occurrences (all)	0	1	1
Neutrophil percentage increased			

subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Platelet count increased			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Prostatic specific antigen increased			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Prothrombin time prolonged			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
White blood cell count increased			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	1 / 67 (1.49%)
occurrences (all)	0	1	1
Injury, poisoning and procedural complications			
Injection related reaction			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			
subjects affected / exposed	2 / 87 (2.30%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	2	1	0
Skin laceration			
subjects affected / exposed	1 / 87 (1.15%)	2 / 67 (2.99%)	0 / 67 (0.00%)
occurrences (all)	1	2	0
Contusion			
subjects affected / exposed	2 / 87 (2.30%)	2 / 67 (2.99%)	1 / 67 (1.49%)
occurrences (all)	3	2	1
Dental restoration failure			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Eye contusion			

subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Eye injury			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Eyelid injury			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Foot fracture			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Hand fracture			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Heat exhaustion			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Ligament sprain			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Limb injury			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	3 / 67 (4.48%)
occurrences (all)	1	0	3
Lisfranc fracture			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Meniscus injury			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Muscle strain			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	1	0	1
Post procedural complication			

subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Post-traumatic pain			
subjects affected / exposed	0 / 87 (0.00%)	2 / 67 (2.99%)	0 / 67 (0.00%)
occurrences (all)	0	2	0
Scratch			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Skin wound			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Stress fracture			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Thermal burn			
subjects affected / exposed	2 / 87 (2.30%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	2	0	0
Traumatic haematoma			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Wrist fracture			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Arrhythmia supraventricular			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Bundle branch block left			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Cardiac failure chronic			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0

Left atrial enlargement subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	1 / 67 (1.49%) 1	0 / 67 (0.00%) 0
Left ventricular hypertrophy subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 67 (0.00%) 0	1 / 67 (1.49%) 1
Palpitations subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	1 / 67 (1.49%) 1	1 / 67 (1.49%) 1
Supraventricular tachycardia subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 67 (0.00%) 0	0 / 67 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 67 (0.00%) 0	1 / 67 (1.49%) 1
Ventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 67 (0.00%) 0	2 / 67 (2.99%) 2
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	3 / 87 (3.45%) 3	2 / 67 (2.99%) 3	3 / 67 (4.48%) 3
Paraesthesia subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 67 (0.00%) 0	0 / 67 (0.00%) 0
Carotid artery stenosis subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	1 / 67 (1.49%) 1	1 / 67 (1.49%) 1
Carpal tunnel syndrome subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 67 (0.00%) 0	0 / 67 (0.00%) 0
Complex regional pain syndrome subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 67 (0.00%) 0	0 / 67 (0.00%) 0
Cubital tunnel syndrome			

subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Epilepsy			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Lacunar infarction			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Occipital neuralgia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Cerebral artery stenosis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Diabetic neuropathy			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Dizziness			
subjects affected / exposed	3 / 87 (3.45%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	3	0	1
Loss of consciousness			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Memory impairment			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Migraine			

subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	1 / 67 (1.49%)
occurrences (all)	0	1	3
Neuropathy peripheral			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Polyneuropathy			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Presyncope			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Radiculopathy			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Vertebrobasilar insufficiency			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	2 / 67 (2.99%)
occurrences (all)	1	0	2
Thrombocytosis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Coagulopathy			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Eosinophilia			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Iron deficiency anaemia			
subjects affected / exposed	2 / 87 (2.30%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	2	0	0
Lymphadenopathy			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0

Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Eye disorders			
Cataract			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	2	0	0
Diabetic retinopathy			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Dermatochalasis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Eyelid ptosis			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Myopia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Eye pain			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Presbyopia			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Visual impairment			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Gastrointestinal disorders			

Diverticulum intestinal			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Hiatus hernia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	2 / 67 (2.99%)
occurrences (all)	1	0	2
Enteritis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal ulcer			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 87 (1.15%)	1 / 67 (1.49%)	1 / 67 (1.49%)
occurrences (all)	1	1	1
Malabsorption			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	1 / 67 (1.49%)
occurrences (all)	0	1	3
Pancreatolithiasis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Umbilical hernia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	1	0	1

Abdominal pain upper			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Colitis			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Constipation			
subjects affected / exposed	2 / 87 (2.30%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	2	0	0
Diarrhoea			
subjects affected / exposed	3 / 87 (3.45%)	3 / 67 (4.48%)	0 / 67 (0.00%)
occurrences (all)	6	3	0
Dysphagia			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Flatulence			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Food poisoning			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	2 / 67 (2.99%)
occurrences (all)	0	0	2
Gastritis			
subjects affected / exposed	0 / 87 (0.00%)	2 / 67 (2.99%)	0 / 67 (0.00%)
occurrences (all)	0	2	0
Gastrointestinal pain			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Haemorrhoids			
subjects affected / exposed	2 / 87 (2.30%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	2	1	0
Impaired gastric emptying			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Inguinal hernia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0

Intestinal polyp subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 67 (0.00%) 0	1 / 67 (1.49%) 1
Irritable bowel syndrome subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 67 (0.00%) 0	1 / 67 (1.49%) 1
Large intestine polyp subjects affected / exposed occurrences (all)	1 / 87 (1.15%) 1	0 / 67 (0.00%) 0	0 / 67 (0.00%) 0
Pancreatitis subjects affected / exposed occurrences (all)	1 / 87 (1.15%) 1	0 / 67 (0.00%) 0	0 / 67 (0.00%) 0
Rectal haemorrhage subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 67 (0.00%) 0	1 / 67 (1.49%) 1
Hepatobiliary disorders Cholelithiasis subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 67 (0.00%) 0	0 / 67 (0.00%) 0
Non-alcoholic fatty liver subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 67 (0.00%) 0	0 / 67 (0.00%) 0
Hepatic cyst subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	1 / 67 (1.49%) 1	1 / 67 (1.49%) 1
Hepatic steatosis subjects affected / exposed occurrences (all)	1 / 87 (1.15%) 1	1 / 67 (1.49%) 1	0 / 67 (0.00%) 0
Hepatomegaly subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 67 (0.00%) 0	0 / 67 (0.00%) 0
Skin and subcutaneous tissue disorders Skin lesion subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 67 (0.00%) 0	0 / 67 (0.00%) 0
Actinic keratosis			

subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Dermatitis allergic			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Psoriasis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Rosacea			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Dermal cyst			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Dermatitis			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Ecchymosis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Hidradenitis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Onychoclasia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Pruritus allergic			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Rash			

subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	2 / 67 (2.99%)
occurrences (all)	1	0	2
Sebacous hyperplasia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Urticaria			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Chronic kidney disease			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	2 / 87 (2.30%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	2	0	0
Hypertonic bladder			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Renal cyst			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	1 / 67 (1.49%)
occurrences (all)	0	1	1
Ureterolithiasis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Urethral stenosis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Acute kidney injury			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Chromaturia			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0

Dysuria			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Leukocyturia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	3 / 87 (3.45%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	4	0	0
Renal impairment			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Urinary retention			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Endocrine disorders			
Hyperparathyroidism			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Hypothyroidism			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Thyroid mass			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	3 / 87 (3.45%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	5	0	1
Osteoarthritis			
subjects affected / exposed	2 / 87 (2.30%)	1 / 67 (1.49%)	1 / 67 (1.49%)
occurrences (all)	2	1	1
Myalgia			
subjects affected / exposed	1 / 87 (1.15%)	2 / 67 (2.99%)	1 / 67 (1.49%)
occurrences (all)	1	2	1
Diffuse idiopathic skeletal hyperostosis			

subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Intervertebral disc protrusion			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Muscle spasms			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	2	0
Osteopenia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Rotator cuff syndrome			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Arthritis			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	1	0	1
Back pain			
subjects affected / exposed	2 / 87 (2.30%)	2 / 67 (2.99%)	2 / 67 (2.99%)
occurrences (all)	2	2	2
Bursitis			
subjects affected / exposed	1 / 87 (1.15%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	1	1	0
Exostosis			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Flank pain			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Joint range of motion decreased			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Mixed connective tissue disease			

subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Neck pain			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Nodal osteoarthritis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Periarthritis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Scleroderma			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Spinal osteoarthritis			
subjects affected / exposed	1 / 87 (1.15%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	1	1	0
Spondylolisthesis			
subjects affected / exposed	2 / 87 (2.30%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	2	0	0
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	7 / 87 (8.05%)	3 / 67 (4.48%)	7 / 67 (10.45%)
occurrences (all)	8	3	7
COVID-19			
subjects affected / exposed	12 / 87 (13.79%)	8 / 67 (11.94%)	11 / 67 (16.42%)
occurrences (all)	12	8	11
Bronchitis			
subjects affected / exposed	1 / 87 (1.15%)	4 / 67 (5.97%)	2 / 67 (2.99%)
occurrences (all)	1	4	2
Cystitis			
subjects affected / exposed	2 / 87 (2.30%)	4 / 67 (5.97%)	2 / 67 (2.99%)
occurrences (all)	5	4	3

Sinusitis			
subjects affected / exposed	2 / 87 (2.30%)	0 / 67 (0.00%)	2 / 67 (2.99%)
occurrences (all)	2	0	2
Lower respiratory tract infection			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Pneumonia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Urinary tract infection			
subjects affected / exposed	7 / 87 (8.05%)	4 / 67 (5.97%)	6 / 67 (8.96%)
occurrences (all)	8	4	6
Abscess neck			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Acute sinusitis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Conjunctivitis			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	1	0	1
Ear infection			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection viral			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0

Viral pharyngitis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Abscess oral			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Bacteriuria			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Body tinea			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Cellulitis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Dermatophytosis of nail			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Diarrhoea infectious			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Diverticulitis			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Fungal skin infection			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Helicobacter infection			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	1 / 87 (1.15%)	2 / 67 (2.99%)	0 / 67 (0.00%)
occurrences (all)	1	2	0

Laryngitis			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Localised infection			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	1	0	1
Meningitis viral			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	2 / 87 (2.30%)	2 / 67 (2.99%)	1 / 67 (1.49%)
occurrences (all)	2	2	1
Otitis media			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Otitis media acute			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Paronychia			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Pharyngitis			
subjects affected / exposed	4 / 87 (4.60%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	4	0	2
Pharyngitis streptococcal			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Post-acute COVID-19 syndrome			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Pyuria			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Respiratory tract infection			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0

Skin infection			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Subcutaneous abscess			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Tinea versicolour			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Tooth infection			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Vaginal infection			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	1 / 67 (1.49%)
occurrences (all)	0	0	1
Viral infection			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	1 / 67 (1.49%)
occurrences (all)	0	2	1
Metabolism and nutrition disorders			
Type 2 diabetes mellitus			
subjects affected / exposed	4 / 87 (4.60%)	5 / 67 (7.46%)	4 / 67 (5.97%)
occurrences (all)	4	5	4
Decreased appetite			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Diabetes mellitus			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Diabetes mellitus inadequate control			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Hyperlipidaemia			

subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Acidosis			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Glucose tolerance impaired			
subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Hyperglycaemia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Hyperkalaemia			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	2	0	0
Hyperuricaemia			
subjects affected / exposed	0 / 87 (0.00%)	2 / 67 (2.99%)	2 / 67 (2.99%)
occurrences (all)	0	2	2
Hypochloraemia			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 87 (0.00%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	2	0	0
Impaired fasting glucose			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Lactose intolerance			

subjects affected / exposed	0 / 87 (0.00%)	1 / 67 (1.49%)	0 / 67 (0.00%)
occurrences (all)	0	1	0
Metabolic acidosis			
subjects affected / exposed	1 / 87 (1.15%)	0 / 67 (0.00%)	0 / 67 (0.00%)
occurrences (all)	1	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 87 (0.00%)	2 / 67 (2.99%)	2 / 67 (2.99%)
occurrences (all)	0	2	2

Non-serious adverse events	ARO-APOC3 50mg Q12W	ARO-APOC3 50mg Q24W	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	48 / 66 (72.73%)	48 / 66 (72.73%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Seborrhoeic keratosis			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	4	
Adrenal adenoma			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Basal cell carcinoma			
subjects affected / exposed	2 / 66 (3.03%)	0 / 66 (0.00%)	
occurrences (all)	2	0	
Benign neoplasm of skin			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Blepharal papilloma			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Fibroma			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Lipoma			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Malignant melanoma in situ			

subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Melanocytic naevus			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 66 (1.52%)	3 / 66 (4.55%)	
occurrences (all)	1	3	
Blood pressure inadequately controlled			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Aortic aneurysm			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Aortic stenosis			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Haematoma			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Hot flush			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Orthostatic hypotension			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 66 (0.00%)	2 / 66 (3.03%)	
occurrences (all)	0	2	
Injection site erythema			
subjects affected / exposed	1 / 66 (1.52%)	2 / 66 (3.03%)	
occurrences (all)	1	3	
Chest discomfort			

subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Influenza like illness			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Oedema			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Oedema peripheral			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Peripheral swelling			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Swelling face			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Dystrophic calcification			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Injection site pain			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	2	0	
Injection site reaction			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Non-cardiac chest pain			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Secretion discharge			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Sensation of foreign body			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Immune system disorders			

Food allergy subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Seasonal allergy subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Social circumstances Postmenopause subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Reproductive system and breast disorders Benign prostatic hyperplasia subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 1	0 / 66 (0.00%) 0	
Erectile dysfunction subjects affected / exposed occurrences (all)	2 / 66 (3.03%) 2	0 / 66 (0.00%) 0	
Fibrocystic breast disease subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Prostatomegaly subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 1	0 / 66 (0.00%) 0	
Emphysema subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 1	3 / 66 (4.55%) 4	
Dyspnoea subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	2 / 66 (3.03%) 2	
Nasal congestion subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	2 / 66 (3.03%) 2	

Asthma			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Hydrothorax			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Upper respiratory tract inflammation			
subjects affected / exposed	1 / 66 (1.52%)	1 / 66 (1.52%)	
occurrences (all)	1	1	
Acquired diaphragmatic eventration			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Bronchial hyperreactivity			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Bronchiectasis			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Dry throat			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Obstructive sleep apnoea syndrome			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Oropharyngeal pain			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Rhinorrhoea			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Upper-airway cough syndrome			

subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Anxiety			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Bipolar disorder			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Depression			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Investigations			
Blood urine present			
subjects affected / exposed	0 / 66 (0.00%)	2 / 66 (3.03%)	
occurrences (all)	0	2	
Glycosylated haemoglobin increased			
subjects affected / exposed	2 / 66 (3.03%)	2 / 66 (3.03%)	
occurrences (all)	2	2	
Amylase increased			
subjects affected / exposed	1 / 66 (1.52%)	1 / 66 (1.52%)	
occurrences (all)	1	1	
Blood creatine phosphokinase increased			
subjects affected / exposed	3 / 66 (4.55%)	1 / 66 (1.52%)	
occurrences (all)	3	1	
Blood creatinine increased			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	2	
Blood pressure increased			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Blood urea increased			

subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Glomerular filtration rate decreased		
subjects affected / exposed	2 / 66 (3.03%)	1 / 66 (1.52%)
occurrences (all)	2	2
Haemoglobin decreased		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Lipase increased		
subjects affected / exposed	3 / 66 (4.55%)	1 / 66 (1.52%)
occurrences (all)	4	1
Pancreatic enzymes increased		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Troponin increased		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Weight decreased		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Alanine aminotransferase increased		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Anion gap increased		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Aspartate aminotransferase increased		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Bilirubin conjugated increased		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Blood bilirubin increased		
subjects affected / exposed	2 / 66 (3.03%)	0 / 66 (0.00%)
occurrences (all)	3	0

Blood glucose increased subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Blood insulin increased subjects affected / exposed occurrences (all)	2 / 66 (3.03%) 2	0 / 66 (0.00%) 0	
Blood iron decreased subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 1	0 / 66 (0.00%) 0	
Blood uric acid increased subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
C-reactive protein increased subjects affected / exposed occurrences (all)	2 / 66 (3.03%) 2	0 / 66 (0.00%) 0	
Cardiac murmur subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Cells in urine subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Electrocardiogram T wave inversion subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 1	0 / 66 (0.00%) 0	
Electrocardiogram abnormal subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 1	0 / 66 (0.00%) 0	
Haematocrit increased			

subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Hepatic enzyme increased			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Human metapneumovirus test positive			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Insulin C-peptide increased			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
International normalised ratio increased			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Laboratory test abnormal			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Neutrophil percentage increased			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Platelet count decreased			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Platelet count increased			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Prostatic specific antigen increased			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Prothrombin time prolonged			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
White blood cell count increased			

subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Injury, poisoning and procedural complications			
Injection related reaction			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Skin abrasion			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Skin laceration			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Contusion			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Dental restoration failure			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Eye contusion			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Eye injury			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Eyelid injury			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Fall			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Foot fracture			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Hand fracture			

subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Heat exhaustion		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Ligament sprain		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Limb injury		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Lisfranc fracture		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Meniscus injury		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Muscle strain		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Post procedural complication		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Post-traumatic pain		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Scratch		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Skin wound		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Stress fracture		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Thermal burn		

subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Traumatic haematoma			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Wrist fracture			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	1 / 66 (1.52%)	1 / 66 (1.52%)	
occurrences (all)	1	1	
Arrhythmia supraventricular			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Bundle branch block left			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Cardiac failure chronic			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Left atrial enlargement			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Left ventricular hypertrophy			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Palpitations			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Supraventricular tachycardia			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Tachycardia			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	

Ventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	4 / 66 (6.06%) 5	5 / 66 (7.58%) 8	
Paraesthesia subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	2 / 66 (3.03%) 2	
Carotid artery stenosis subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	1 / 66 (1.52%) 1	
Carpal tunnel syndrome subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 1	1 / 66 (1.52%) 1	
Complex regional pain syndrome subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	1 / 66 (1.52%) 1	
Cubital tunnel syndrome subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	1 / 66 (1.52%) 2	
Epilepsy subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 1	1 / 66 (1.52%) 2	
Hypoaesthesia subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 1	1 / 66 (1.52%) 1	
Lacunar infarction subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	1 / 66 (1.52%) 1	
Occipital neuralgia subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	1 / 66 (1.52%) 1	
Sciatica			

subjects affected / exposed	1 / 66 (1.52%)	1 / 66 (1.52%)
occurrences (all)	1	1
Syncope		
subjects affected / exposed	1 / 66 (1.52%)	1 / 66 (1.52%)
occurrences (all)	1	1
Cerebral artery stenosis		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Diabetic neuropathy		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Dizziness		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Loss of consciousness		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Memory impairment		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Migraine		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Neuropathy peripheral		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Polyneuropathy		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Presyncope		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Radiculopathy		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Vertebrobasilar insufficiency		

subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 1	0 / 66 (0.00%) 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 66 (1.52%)	1 / 66 (1.52%)	
occurrences (all)	1	1	
Thrombocytosis			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Coagulopathy			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Eosinophilia			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Iron deficiency anaemia			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Lymphadenopathy			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Vertigo			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Eye disorders			
Cataract			
subjects affected / exposed	0 / 66 (0.00%)	2 / 66 (3.03%)	
occurrences (all)	0	2	
Diabetic retinopathy			
subjects affected / exposed	0 / 66 (0.00%)	2 / 66 (3.03%)	
occurrences (all)	0	2	
Dermatochalasis			

subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Eyelid ptosis			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Myopia			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Dry eye			
subjects affected / exposed	2 / 66 (3.03%)	0 / 66 (0.00%)	
occurrences (all)	2	0	
Eye pain			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Presbyopia			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Visual impairment			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal disorders			
Diverticulum intestinal			
subjects affected / exposed	0 / 66 (0.00%)	2 / 66 (3.03%)	
occurrences (all)	0	2	
Hiatus hernia			
subjects affected / exposed	0 / 66 (0.00%)	2 / 66 (3.03%)	
occurrences (all)	0	2	
Abdominal pain			
subjects affected / exposed	4 / 66 (6.06%)	1 / 66 (1.52%)	
occurrences (all)	4	1	
Dyspepsia			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Enteritis			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	

Gastrointestinal ulcer		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Gastrooesophageal reflux disease		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Malabsorption		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Nausea		
subjects affected / exposed	2 / 66 (3.03%)	1 / 66 (1.52%)
occurrences (all)	2	1
Pancreatolithiasis		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Umbilical hernia		
subjects affected / exposed	1 / 66 (1.52%)	1 / 66 (1.52%)
occurrences (all)	1	1
Vomiting		
subjects affected / exposed	2 / 66 (3.03%)	1 / 66 (1.52%)
occurrences (all)	2	1
Abdominal pain upper		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Colitis		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Constipation		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Diarrhoea		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Dysphagia		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0

Flatulence		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Food poisoning		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Gastritis		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Gastrointestinal pain		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Haemorrhoids		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	2	0
Impaired gastric emptying		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Inguinal hernia		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Intestinal polyp		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Irritable bowel syndrome		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Large intestine polyp		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Pancreatitis		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Rectal haemorrhage		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0

Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	2	
Non-alcoholic fatty liver			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Hepatic cyst			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Hepatic steatosis			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Hepatomegaly			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Skin and subcutaneous tissue disorders			
Skin lesion			
subjects affected / exposed	0 / 66 (0.00%)	2 / 66 (3.03%)	
occurrences (all)	0	2	
Actinic keratosis			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Dermatitis allergic			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Psoriasis			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	2	
Rosacea			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Skin ulcer			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Alopecia			

subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Dermal cyst			
subjects affected / exposed	2 / 66 (3.03%)	0 / 66 (0.00%)	
occurrences (all)	2	0	
Dermatitis			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Ecchymosis			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Hidradenitis			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Onychoclasia			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Pruritus allergic			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Rash			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Sebaceous hyperplasia			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Urticaria			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	2 / 66 (3.03%)	2 / 66 (3.03%)	
occurrences (all)	2	2	
Chronic kidney disease			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	

Haematuria		
subjects affected / exposed	2 / 66 (3.03%)	1 / 66 (1.52%)
occurrences (all)	2	1
Hypertonic bladder		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Renal cyst		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Ureterolithiasis		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Urethral stenosis		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Acute kidney injury		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Chromaturia		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Dysuria		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Leukocyturia		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	2	0
Proteinuria		
subjects affected / exposed	2 / 66 (3.03%)	0 / 66 (0.00%)
occurrences (all)	2	0
Renal impairment		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Urinary retention		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0

Endocrine disorders			
Hyperparathyroidism			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Hypothyroidism			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Thyroid mass			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 66 (3.03%)	4 / 66 (6.06%)	
occurrences (all)	2	5	
Osteoarthritis			
subjects affected / exposed	0 / 66 (0.00%)	3 / 66 (4.55%)	
occurrences (all)	0	3	
Myalgia			
subjects affected / exposed	0 / 66 (0.00%)	2 / 66 (3.03%)	
occurrences (all)	0	2	
Diffuse idiopathic skeletal hyperostosis			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Intervertebral disc protrusion			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Muscle spasms			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Osteopenia			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Pain in extremity			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	
Rotator cuff syndrome			

subjects affected / exposed	1 / 66 (1.52%)	1 / 66 (1.52%)
occurrences (all)	1	1
Arthritis		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Back pain		
subjects affected / exposed	4 / 66 (6.06%)	0 / 66 (0.00%)
occurrences (all)	4	0
Bursitis		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Exostosis		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Flank pain		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Joint range of motion decreased		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Mixed connective tissue disease		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Musculoskeletal pain		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Neck pain		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Nodal osteoarthritis		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Periarthritis		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Scleroderma		

subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Spinal osteoarthritis			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Spondylolisthesis			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	2 / 66 (3.03%)	9 / 66 (13.64%)	
occurrences (all)	2	10	
COVID-19			
subjects affected / exposed	9 / 66 (13.64%)	6 / 66 (9.09%)	
occurrences (all)	9	6	
Bronchitis			
subjects affected / exposed	3 / 66 (4.55%)	5 / 66 (7.58%)	
occurrences (all)	3	5	
Cystitis			
subjects affected / exposed	1 / 66 (1.52%)	4 / 66 (6.06%)	
occurrences (all)	2	7	
Sinusitis			
subjects affected / exposed	0 / 66 (0.00%)	4 / 66 (6.06%)	
occurrences (all)	0	4	
Lower respiratory tract infection			
subjects affected / exposed	1 / 66 (1.52%)	2 / 66 (3.03%)	
occurrences (all)	1	2	
Pneumonia			
subjects affected / exposed	0 / 66 (0.00%)	2 / 66 (3.03%)	
occurrences (all)	0	2	
Urinary tract infection			
subjects affected / exposed	6 / 66 (9.09%)	2 / 66 (3.03%)	
occurrences (all)	7	3	
Abscess neck			
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)	
occurrences (all)	0	1	

Acute sinusitis		
subjects affected / exposed	1 / 66 (1.52%)	1 / 66 (1.52%)
occurrences (all)	1	1
Conjunctivitis		
subjects affected / exposed	1 / 66 (1.52%)	1 / 66 (1.52%)
occurrences (all)	1	1
Ear infection		
subjects affected / exposed	1 / 66 (1.52%)	1 / 66 (1.52%)
occurrences (all)	1	1
Hordeolum		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	2
Oral candidiasis		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Respiratory tract infection viral		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Rhinitis		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Viral pharyngitis		
subjects affected / exposed	0 / 66 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	1
Abscess oral		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Bacteriuria		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Body tinea		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Cellulitis		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0

Dermatophytosis of nail		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Diarrhoea infectious		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Diverticulitis		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Fungal skin infection		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Gastroenteritis		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Helicobacter infection		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Influenza		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Laryngitis		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Localised infection		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Meningitis viral		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Nasopharyngitis		
subjects affected / exposed	2 / 66 (3.03%)	0 / 66 (0.00%)
occurrences (all)	2	0
Otitis media		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0

Otitis media acute		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Paronychia		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Pharyngitis		
subjects affected / exposed	2 / 66 (3.03%)	0 / 66 (0.00%)
occurrences (all)	2	0
Pharyngitis streptococcal		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Post-acute COVID-19 syndrome		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Pyuria		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Respiratory tract infection		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Skin infection		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Subcutaneous abscess		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Tinea versicolour		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0
Tooth abscess		
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0
Tooth infection		
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)
occurrences (all)	1	0

Vaginal infection subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Viral infection subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Metabolism and nutrition disorders			
Type 2 diabetes mellitus subjects affected / exposed occurrences (all)	8 / 66 (12.12%) 8	11 / 66 (16.67%) 11	
Decreased appetite subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	1 / 66 (1.52%) 2	
Diabetes mellitus subjects affected / exposed occurrences (all)	2 / 66 (3.03%) 2	1 / 66 (1.52%) 1	
Diabetes mellitus inadequate control subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 2	1 / 66 (1.52%) 1	
Hyperlipidaemia subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	1 / 66 (1.52%) 1	
Hypokalaemia subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	1 / 66 (1.52%) 1	
Hypophosphataemia subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 1	1 / 66 (1.52%) 1	
Acidosis subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Glucose tolerance impaired subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0	0 / 66 (0.00%) 0	
Hyperglycaemia			

subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Hyperkalaemia			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Hyperuricaemia			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Hypochloraemia			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Hypoglycaemia			
subjects affected / exposed	1 / 66 (1.52%)	0 / 66 (0.00%)	
occurrences (all)	1	0	
Hyponatraemia			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Impaired fasting glucose			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Lactose intolerance			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Metabolic acidosis			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	
Vitamin D deficiency			
subjects affected / exposed	0 / 66 (0.00%)	0 / 66 (0.00%)	
occurrences (all)	0	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 May 2022	<ul style="list-style-type: none">- Requirements for the study design to strengthen reporting criteria for SAEs- Amend requirements to suspend dosing in subjects- To allow a documented prior history of elevated TG between ≥ 150 mg/dL and ≤ 499 mg/dL (≥ 1.69 and ≤ 5.64 mmol/L) on 1 occasion is adequate to identify the study population targeted for inclusion- To extend the timeframe between the first and second qualifying fasting TG collection by 3 days- Inclusion criteria were updated to allow use of anticoagulation therapy, thyroid hormone therapy, and testosterone replacement therapy.- The PK endpoint was clarified and was redefined as an exploratory endpoint because it is not a main focus of the study.- Additional details were available regarding the primary analysis method and secondary endpoint analysis. Clarified the timing of the final clinical study report.- Updated the table and footnotes in the schedule of events table to clarify assessments and associated timepoints and to be consistent with updated sections of the protocol.- Included the final results from clinical study AROAPOC31001.- Added a new subsection to describe Benefit-Risk assessment for plozasiran.- Clarification that the timepoint begins with the lipid parameter collected at the Week 24 visit.- Time window for Screening visit 3 was extended to 17 days to lessen study burden on study subjects and investigative site staff. Text was updated to more accurately describe dosing visits.- Added guidance regarding the method to determine LDL-C eligibility.- To clarify that use of spermicide is not required when using a condom.- Updated the reporting requirements for pregnancy for consistency with existing procedure.
17 May 2022	(continued) <ul style="list-style-type: none">- Updated that Day 1 predose assessment and 2 fasting TG values during the Screening period was to account for result fluctuations and provide a more stable measurement to represent the baseline TG level. Additional details were available regarding the statistical analyses, including the estimand (ICH E9 [R1] addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials), the baseline\definition for lipid-related lipoprotein and serum PD assessments.- Updated study discontinuation criteria.- Added measures taken to protect personal data collected in the course of study conduct
22 November 2022	<ul style="list-style-type: none">- Added text to footnote 6 of the SOA: HbA1c was to be evaluated on an ongoing basis against treatment discontinuation criteria (Appendix 3).- Definition of HbA1c revised from "Glycosylated hemoglobin" to "Glycated hemoglobin". Added OLE to the list.- Added guidelines for new study drug discontinuation rules in response to HbA1c elevation.- Added mitigation steps and reference to study drug discontinuation criteria in response HbA1c elevation.- Provided information on the administrative analysis and the increased HbA1c levels in relation to Benefit-Risk analysis.- Added the following text: "In response to diabetes evaluations, adjustments to treatment medication are allowed at the discretion of the PI".- Added new Appendix 3.

26 January 2023	- Added text describing a planned interim analysis.
-----------------	---

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported